is a parasite that causes bilharzia, a neglected tropical disease affecting hundreds of millions of people each year worldwide. In 2012, had been identified as the only invertebrate possessing two SERCA-type Ca-ATPases, SMA1 and SMA2. However, our analysis of recent genomic data shows that the presence of two SERCA pumps is rather frequent in parasitic flatworms. To understand the reasons of this redundancy in , we compared SMA1 and SMA2 at different levels. In terms of sequence and organization, the genes and are similar, suggesting that they might be the result of a duplication event. At the protein level, SMA1 and SMA2 only slightly differ in length and in the sequence of the nucleotide-binding domain. To get functional information on SMA1, we produced it in an active form in , as previously done for SMA2. Using phosphorylation assays from ATP, we demonstrated that like SMA2, SMA1 bound calcium in a cooperative mode with an apparent affinity in the micromolar range. We also showed that SMA1 and SMA2 had close sensitivities to cyclopiazonic acid but different sensitivities to thapsigargin, two specific inhibitors of SERCA pumps. On the basis of transcriptomic data available in GeneDB, we hypothesize that SMA1 is a housekeeping Ca-ATPase, whereas SMA2 might be required in particular striated-like muscles like those present the tail of the cercariae, the infecting form of the parasite.

Download full-text PDF

Source
http://dx.doi.org/10.1042/BCJ20170355DOI Listing

Publication Analysis

Top Keywords

sma1 sma2
16
sma1
8
serca pumps
8
sma2
7
functional characterization
4
characterization ca-atpase
4
ca-atpase sma1
4
sma1 parasite
4
parasite bilharzia
4
bilharzia neglected
4

Similar Publications

Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy.

Sci Rep

October 2024

Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, UK.

Article Synopsis
  • * In a study of 20 children with SMA, specific neuroinflammatory markers like MCP-1, IL-7, and IL-8 were linked to disease severity, with notable changes observed after treatment with nusinersen over six months.
  • * The treatment led to decreased levels of eotaxin and MIP-1β, correlating with improved motor function, while other markers showed a temporary increase shortly after nusinersen injections, suggesting an initial inflammatory response that eventually normalized.
View Article and Find Full Text PDF

Aim: The availability of disease-modifying therapies and newborn screening programs for spinal muscular atrophy (SMA) has generated an urgent need for reliable prognostic biomarkers to classify patients according to disease severity. We aim to identify cerebrospinal fluid (CSF) prognostic protein biomarkers in CSF samples of SMA patients collected at baseline (T0), and to describe proteomic profile changes and biological pathways influenced by nusinersen before the sixth nusinersen infusion (T302).

Methods: In this multicenter retrospective longitudinal study, we employed an untargeted liquid chromatography mass spectrometry (LC-MS)-based proteomic approach on CSF samples collected from 61 SMA patients treated with nusinersen (SMA1 n=19, SMA2 n=19, SMA3 n=23) at T0 at T302.

View Article and Find Full Text PDF

Objective: To elucidate the clinical characteristics and standard of care (SoC) of spinal muscular atrophy (SMA) patients in Thailand, focusing on primary endpoints: age at death and a composite of death or tracheostomy need.

Design: Retrospective observational study.

Setting: Seven tertiary centres across Thailand.

View Article and Find Full Text PDF

Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.

Int J Mol Sci

August 2024

NIHR Great Ormond Street Hospital Biomedical Research Centre and Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.

Article Synopsis
  • Ongoing clinical trials are investigating the use of myostatin inhibitors to enhance muscle mass in patients with spinal muscular atrophy (SMA), but restoring normal myostatin levels may be necessary first.
  • A study analyzed myostatin and follistatin levels in 25 SMA patients before and after treatment with nusinersen, examining their correlation with disease severity and motor function over time.
  • Although some relationships between myostatin levels and motor function were found, there was no significant effect of nusinersen on myostatin or follistatin levels, indicating the need for further research on the impact of disease-modifying treatments on these proteins and patient selection for future trials.
View Article and Find Full Text PDF

Cognition and communication in patients with spinal muscular atrophy: A systematic review.

Heliyon

July 2024

Université Libre de Bruxelles, ULB, Hôpital Universitaire de Bruxelles (HUB), Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Department of Paediatric Neurology and Neuromuscular Reference Center, Brussels, Belgium.

•Synthesizes evidence from 12 studies on cognitive and communicative impacts in SMA, focusing on nuanced functional outcomes.•Highlights cognitive variability in SMA1, revealing subtle challenges in SMA2 and 3, and stresses tailored assessment methodologies.•Identifies communication barriers in SMA, emphasizing the urgency of investigating their potential interplay with cognitive functions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!